| Literature DB >> 35805098 |
Kanokphong Suparan1,2,3,4, Sirawit Sriwichaiin2,3,4, Nipon Chattipakorn2,3,4, Siriporn C Chattipakorn2,3,5.
Abstract
The human gut microbiome is acknowledged as being associated with homeostasis and the pathogenesis of several diseases. Conventional culture techniques are limited in that they cannot culture the commensals; however, next-generation sequencing has facilitated the discovery of the diverse and delicate microbial relationship in body sites and blood. Increasing evidence regarding the blood microbiome has revolutionized the concept of sterility and germ theory in circulation. Among the types of microbial communities in the blood, bacteriomes associated with many health conditions have been thoroughly investigated. Blood bacterial profiles in healthy subjects are identified as the eubiotic blood bacteriome, whereas the dysbiotic blood bacteriome represents the change in bacterial characteristics in subjects with diseases showing deviations from the eubiotic profiles. The blood bacterial characteristics in each study are heterogeneous; thus, the association between eubiotic and dysbiotic blood bacteriomes and health and disease is still debatable. Thereby, this review aims to summarize and discuss the evidence concerning eubiotic and dysbiotic blood bacteriomes characterized by next-generation sequencing in human studies. Knowledge pertaining to the blood bacteriome will transform the concepts around health and disease in humans, facilitating clinical implementation in the near future.Entities:
Keywords: bacteriome; blood; dysbiosis; eubiotic; microbiome
Mesh:
Year: 2022 PMID: 35805098 PMCID: PMC9265464 DOI: 10.3390/cells11132015
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 7.666
Eubiotic Characteristics of the Blood Bacteriome in Healthy Humans.
| Blood Specimen | Subjects | Age # | Country | Hypervariable | Taxonomic Database | Order of Relative Abundance at Phylum Level | Ref. | |||
|---|---|---|---|---|---|---|---|---|---|---|
| First | Second | Third | Other | |||||||
| DNA | ||||||||||
| Whole blood | 10 (9/1) | 29.2 ± 11.26 | India | V3 | Greengenes | Proteobacteria | Firmicutes | Actinobacteria | NA | [ |
| 12 (10/2) | 29.2 ± 3.8 | China | V3 | RDP | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes | [ | |
| 3 (2/1) | 38.33 ± 20.98 | UK | V3–V4 | SILVA | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes, Fusobacteria | [ | |
| 60 (18/42) | 39.8 ± 9.5 | Italian | V3–V4 | NCBI | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes | [ | |
| 19 (4/15) | 39.89 ± 13.69 | UK | V3–V4 | SILVA | Firmicutes | Proteobacteria | Actinobacteria | Bacteroidetes, Fusobacteria | [ | |
| 20 (5/15) | 41.9 ± 10.7 | USA | V3–V4 | Greengenes | Firmicutes | Proteobacteria | Actinobacteria | Bacteroidetes | [ | |
| 28 (14/14) | 45 ± 12 | Bulgaria | V3–V4 | Greengenes | Proteobacteria | Firmicutes | Actinobacteria | Planctomycetes | [ | |
| 28 (14/14) | 45 ± 12 | Bulgaria | V3–V4 | Greengenes | Proteobacteria | Firmicutes | Actinobacteria | Bacteroidetes, Cyanobacteria | [ | |
| 23 (10/13) | 59 | Poland | V3–V4 | RDP, Greengenes | Actinobacteria | Proteobacteria | Firmicutes | Bacteroidetes, Cyanobacteria | [ | |
| 28 (NA) | NA | China | V3, V4, V3–V4, V4–V5 | Greengenes | Firmicutes | Bacteroidetes | Proteobacteria | Actinobacteria, Cyanobacteria | [ | |
| 5 (NA) | NA | China | V3 | RDP | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes | [ | |
| 28 (NA) | NA | Bulgaria | V3–V4 | SILVA | Proteobacteria | Firmicutes | Actinobacteria | Planctomycetes, Armatimonadetes | [ | |
| 28 (NA) | NA | Bulgaria | V3–V4 | SILVA | Proteobacteria | Firmicutes | Actinobacteria | Bacteroidetes, Fusobacteria | [ | |
| Buffy coat | 30 (9/21) | 21 (18–53) | France | V3–V4 | NCBI | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes | [ |
| 15 (15/0) | 40 (25–68) | Denmark | V3–V4 | NCBI, SILVA | Proteobacteria | Actinobacteria | Firmicutes | Acidobacteria, Bacteroidetes | [ | |
| 20 (7/13) | 44 (39–53) | USA | V3–V4 | SILVA | Proteobacteria | Bacteroidetes | Actinobacteria | Firmicutes | [ | |
| 26 (5/21) | 46.2 ± 8.9 | Spain | V3–V4 | NCBI | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes | [ | |
| 28 (NA) | 47 ± 10 | France | V1–V2 | SILVA | Proteobacteria | Bacteroidetes | Actinobacteria | Firmicutes, Acidobacteria | [ | |
| Neutrophil | 12 (10/2) | 29.2 ± 3.8 | China | V3 | RDP | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes | [ |
| 5 (NA) | NA | China | V3 | RDP | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes | [ | |
| PBMC | 14 (0/15) | 50.48 ± 14.05 | China | V3–V4 | SILVA | Proteobacteria | Actinobacteria | Bacteroidetes | Deinococcus–Thermus, Firmicutes | [ |
| Red blood cell | 30 (9/21) | 21 (18–53) | France | V3–V4 | NCBI | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes, Fusobacteria | [ |
| Serum | 24 (10/14) | 27.8 ± 4.0 | USA | V4 | RDP | Firmicutes | Bacteroidetes | Proteobacteria | Fusobacteria, Actinobacteria | [ |
| 201 (119/82) | 57.6 ± 10.4 | Korea | V3–V4 | Greengenes | Firmicutes | Proteobacteria | Actinobacteria | Bacteroidetes, Verrucomicrobia | [ | |
| 24 (10/14) | 63.9 ± 3.2 | USA | V4 | RDP | Firmicutes | Bacteroidetes | Proteobacteria | Actinobacteria, Fusobacteria | [ | |
| 13 (NA) | NA | China | V1–V2 | RDP, Greengenes | Proteobacteria | Actinobacteria | Firmicutes | Deinococcus–Thermus, Bacteroidetes | [ | |
| 4 (NA) | NA | UK | V4 | SILVA | Proteobacteria | Firmicutes | Bacteroidetes | Actinobacteria, Fusobacteria | [ | |
| 15 (NA) | NA | France | V3–V4 | Greengenes | Proteobacteria | Bacteroidetes | Actinobacteria | Firmicutes, Gemmatimonadetes | [ | |
| Plasma | 30 (9/21) | 21 (18–53) | France | V3–V4 | NCBI | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes | [ |
| 3 (2/1) | 27 ± 3.46 | India | Shotgun | MG-RAST/ SEED | Proteobacteria | Actinobacteria | Firmicutes | NA | [ | |
| 15 (15/0) | 29 (24–33) | Italy | V3–V4 | NCBI, SILVA | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes | [ | |
| 19 (0/19) | 34.2 ± 9.4 | USA | V4 | Greengenes | Proteobacteria | Fusobacteria | Actinobacteria | Firmicutes, Bacteroidetes | [ | |
| 16 (5/11) | 38 (33–55) | USA | V4 | NCBI, RDP | Proteobacteria | Firmicutes | Actinobacteria | Bacteroidetes | [ | |
| 18 (3/15) | 38.6 ± 12.4 | USA | V4 | Greengenes | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes, Cyanobacteria | [ | |
| 5 (0/5) | 39.4 ± 10.3 | UK | V4 | SILVA | Proteobacteria | Actinobacteria | Firmicutes | Bacteroidetes | [ | |
| 150 (66/84) | 48.13 ± 6.22 | China | V6–V7 | NA | Proteobacteria | Firmicutes | Actinobacteria | Bacteroidetes | [ | |
| 100 (64/36) | 51.98 ± 8.05 | China | V5–V6 | NA | Proteobacteria | Bacteroidetes | Firmicutes | Actinobacteria | [ | |
| EVs | 8 (5/3) | 49.63 ± 15.16 | Taiwan | V1–V9 | NCBI | Proteobacteria | Firmicutes | Actinobacteria | Bacteroidetes, Fusobacteria | [ |
| 88 (37/51) | 54.4 ± 12.8 | Korea | V3–V4 | Greengenes | Proteobacteria | Firmicutes | Actinobacteria | Bacteroidetes, Cyanobacteria | [ | |
| 260 (105/155) | 56 | Korea | V3–V4 | SILVA | Firmicutes | Proteobacteria | Actinobacteria | Bacteroidetes, Verrucomicrobia | [ | |
| 200 (117/83) | 63.5 ± 12.5 | Korea | V3–V4 | Greengenes | Firmicutes | Bacteroidetes | Proteobacteria | Verrucomicrobia, Actinobacteria | [ | |
| 5 (NA) | NA | UK | V3–V4 | SILVA | Proteobacteria | Firmicutes | Actinobacteria | Bacteroidetes, Fusobacteria | [ | |
|
| ||||||||||
| Whole blood | 14 (12/1) | 37.4 ± 10 | Japan | V3–V4 | Greengenes | Firmicutes | Bacteroidetes | Fusobacteria | Proteobacteria, Actinobacteria | [ |
| 49 (38/11) | 41.1 ± 10.7 | USA | RNA-Seq | PhyloSift | Proteobacteria | Firmicutes | Cyanobacteria | Bacteroidetes, Thermotogae | [ | |
| Plasma | 5 (0/5) | 39.4 ± 10.3 | UK | RNA-Seq | Kraken/ | Proteobacteria | Firmicutes | Bacteroidetes | Actinobacteria | [ |
# Age expressed by mean ± SD or median with interquartile range; † specimens were pretreated by DNase before the DNA extraction; ‡ specimens were pretreated by resuscitation process before DNA extraction.
Blood Bacteriome Dysbiosis Profiles in Infection-Related Diseases.
| Subjects (n; Mean Age) | Samples | Dysbiotic Blood Bacteriome of Patients vs. Controls | Other | Interpretation | Ref. | |||
|---|---|---|---|---|---|---|---|---|
| Diversity | Differential Abundance | |||||||
| α-R | α-E | β | ||||||
|
| ||||||||
| The Italian study (56): HIV patients before treatment with cART (41; age = 42 (31.5–50.5)) HC (15; age = 29 (24–33)) | Plasma | ↑ | ↑ | NA | NA | Blood dysbiosis in HIV infection might be characterized by an increase in | [ | |
| The Italian study (41; age = 42 (31.5–50.5)): HIV patients after treatment with cART for 2 years (41) NNRTI (25; age = NA) PI (9; age = NA) INI (7; age = NA) HIV patients before treatment with cART (41) | Plasma | ↕ | ↕ | NS | NA | cART could modify blood bacteriome with an increase in | [ | |
|
| ||||||||
|
| ||||||||
| NA | NA | NA |
↑Endotoxin core antibody ↑Intestinal fatty acid-binding protein | HIV infection treated with either NNRTI or PI may lead to an increase in disruption of the gut epithelial barrier, and NNRTI could distinctly modify blood bacteriome by an increase in | ||||
| The American study (91): HIV patients with cART (40; age = 42 (38–51)) HC (51; age = 42 (35–48)) | Plasma | NA | NA | S |
↑TNF-α, ↑IL-1β, and ↑IL-6 from PBMC inoculated with | An increase in | [ | |
| The American study (42): HIV patients after receiving influenza vaccines (26; age = NA) High anti-nuclear antibody after vaccination (12; age = 43 (36–54)) Low anti-nuclear antibody after vaccination (14; age = 43 (26–52)) HC after receiving influenza vaccines (16; age = 38 (33–55)) | Plasma | NA | ↕ | NS |
↑anti-nuclear antibody in the HIV patients after receiving influenza vaccines vs. HC | Blood dysbiosis in HIV infection could initiate production of autoantibody, which may be characterized by an increase in Proteobacteria, | [ | |
|
| ||||||||
|
| ||||||||
| NA | ↕ | NS |
↑anti-dsDNA antibody in mice inoculated with heat-killed | An increased proportion of | ||||
|
| ||||||||
| The Polish study (85): Patients with sepsis (62; age = 67) HC (23; age = 59) | Whole blood | ↑ | NA | S | NA | Blood dysbiosis in sepsis might be characterized by an increase in Proteobacteria but a decrease in Actinobacteria, Bifidobacteriales in particular | [ | |
| The Chinese study (51): Post-operative patients with infection (39; age = 54.21 ± 14.01) No sepsis (10; age = 49.4 ± 17.9) Sepsis (18; age = 54.2 ± 12.3) Septic shock, SS (11; age = 58.6 ± 13.4) Controls (12; age = NA) Non-infected (7; age = 49.6 ± 10.5) HC (5; age = NA) | Whole blood | ↓ | NA | S | NA |
About 80% of blood bacteriome was familiar with gut microbiome (HMP database) | Blood dysbiosis in post-operative patients with infection may originate from the gut microbiome, and | [ |
|
| ||||||||
|
| ||||||||
| NA | NA | NA | NA | Blood dysbiosis in septic shock may be characterized by an increase in Bacteroidetes but a decrease in Actinobacteria | ||||
| The Chinese study (34): Post-operative patients with sepsis (29; age = 55.87 ± 12.71) Sepsis, S (18; age = 54.2 ± 12.3) Septic shock, SS (11; age = 58.6 ± 13.4) HC (5; age = NA) | Neutrophil | ↑ | NA | S |
About 80% of neutrophil bacteriome were familiar with gut microbiome (HMP database) | Neutrophil bacteriome in post-operative patients with sepsis may originate from the gut microbiome and be characterized by an increase in Proteobacteria but a decrease in Actinobacteria | [ | |
| The American study (30): PICC-inserted neonates with CLABSI (15; GA = 30 ± 5 weeks) PICC-inserted neonates without CLABSI (15; GA = 32 ± 6 weeks) | Whole blood | ↕ | ↕ | S |
| Blood dysbiosis of CLABSI might be associated with ascending infection from catheter biofilm | [ | |
|
| ||||||||
| The Korean study (41): Pregnant women (21; age = 30.91 ± 4.37) who experienced pre-term delivery at GA 29.67 ± 3.58 weeks Pregnant women (20; age = 31.60 ± 2.91) who experienced term delivery at GA 39.65 ± 1.04 weeks | Plasma-separated blood cell | ↑ | NA | S | NA | Blood dysbiosis in pregnant women who had pre-term delivery might be characterized by an increase in Firmicutes and Bacteroidetes but a decrease in Proteobacteria | [ | |
| The American study (40): Pregnant women (20; age = 22.9 ± 2.7) who later experienced pre-term delivery at GA 29.0 (25.8–30.8) weeks Pregnant women (20; age = 22.7 ± 4.3) who later experienced term delivery at GA 39.6 (39.3–41.1) weeks | Serum | ↑ | ↑ | S | NA | Blood dysbiosis in mid-trimester pregnant women who had pre-term delivery might be characterized by an increase in Proteobacteria and Actinobacteria but a decrease in Firmicutes and Bacteroidetes | [ | |
Age: expressed by mean ± SD or median with interquartile range; Alpha-diversity indices (α): R, richness (either Shannon, phylogenic diversity whole tree, operational taxonomic unit (OTU) counts or Chao1); E, evenness (either Simpson or observed OTU); ↑, significant increase; ↓, significant decrease; ↕, insignificant difference; Beta-diversity indices (β): NS, insignificant difference of Bray-Curtis dissimilarity or unclear separation by principal coordinate analysis (PCoA) plot; S, either significant difference of Bray–Curtis dissimilarity or clear separation by PCoA plot.
Blood Bacteriome Dysbiosis Profiles in Age-Related Metabolic Diseases.
| Subjects (n; Mean Age) | Samples | Dysbiotic Blood Bacteriome Patients vs. Controls | Other | Interpretation | Ref. | |||
|---|---|---|---|---|---|---|---|---|
| Diversity | Differential Abundance | |||||||
| α-R | α-E | β | ||||||
|
| ||||||||
| The French study (42): HC who, later, were diagnosed with T2DM (14; age = NA) HC (28; age = NA) | Buffy coat | NA | NA | NA |
↑16s rRNA gene concentration in the HC who, later, were diagnosed with T2DM | Blood dysbiosis characterized by an increase in Proteobacteria and a decrease in Actinobacteria as well as an upsurge in baseline 16s rRNA gene concentration may be involved in the development of T2DM in healthy subjects | [ | |
| The Chinese study (150): T2DM patients (50; age = 51.64 ± 6.18) HC (100; age = 51.98 ± 8.05) | Plasma | ↕ | ↕ | NA |
| Blood dysbiosis in T2DM might be characterized by a decrease in Rhodospirillales together with Myxococcales, and | [ | |
| The Canadian study (40): Morbid obese patients with T2DM (20; age = 42 ± 9; BMI = 50.9 ± 9.1) Morbid obese patients without T2DM (20; age = 41 ± 9; BMI = 50.2 ± 7.9) | Plasma | ↕ | ↕ | NS |
↑16s rRNA gene concentration in liver compared with blood in the overall subjects | Blood dysbiosis in morbid obesity with T2DM might be characterized by an increase in | [ | |
| The German study (75): Morbid obese patients with T2DM (33; age = 52.5 ± 11.3; BMI = 48.8 ± 7.4) Morbid obese patients without T2DM (42; age = 45.2 ± 11.0; BMI = 47.2 ± 5.8) | Plasma | ↕ | ↕ | NA |
↑Diversity in bacteriome of mesenteric adipose tissues in the overall subjects ↑TNF-α, ↑IL-6, ↑CRP, and ↑LBP from Bacterial-DNA-inoculated adipocytes | Blood dysbiosis in T2DM might be characterized by an increase in | [ | |
| The Danish study (29): Obese patients (14; age = 32 (25–58); BMI = 33.4 (30.9–39.8)) HC (15; age = 40 (25–68); BMI = 23.8 (20.7–25.0)) | Buffy coat | ↕ | NA | NA |
16s rRNA gene concentration in liver correlated with severity of fatty liver (r = 0.44) ↑Diversity in liver bacteriome of the obese patients vs. HC ↑Proteobacteria in liver bacteriome of the obese patients vs. HC | Blood dysbiosis in obesity might be characterized by an increase in Propionibactereles, Sphingomonadales, and Norcardioides; moreover, liver might filter microbes in blood, especially Proteobacteria, and an increase in 16s rRNA gene concentration in liver might play a role in pathogenesis of fatty liver | [ | |
|
| ||||||||
| The Chinese study (69): Patients with hypertension (41; age = NA) HC (28; age = NA) | Whole blood | ↕ | ↕ | S |
Blood bacteriome might primarily originate from gastroenteritis, diarrhea, and pneumonia (FAPROTAX database) | Blood dysbiosis in hypertension might be characterized by an increase in | [ | |
| The Chinese study (300): Patients with hypertension (150; age = 47.67 ± 6.02) HC (150; age = 48.13 ± 6.22) | Plasma | ↓ | ↕ | NA |
| Blood dysbiosis in hypertension might be characterized by an increase in Proteobacteria but a decrease in Firmicutes and Bacteroidetes; furthermore, | [ | |
|
| ||||||||
| The Indian study (41): Patients with cardiac diseases (31; age = 36.55 ± 18.50) VHD (13; age = 31.15 ± 12.19) IHD (11; age = 54.55 ± 6.30) CHD (7; age = 18.29 ± 11.94) HC (10; age = 29.20 ± 11.26) | Whole blood | NA | NA | NA | NA | Blood dysbiosis in cardiac diseases might be characterized by an increase in Proteobacteria but a decrease in Firmicutes | [ | |
| The Indian study (6): Patients with cardiac diseases (3; age = 33 ± 17.35) VHD (1; age = 44) IHD (1; age = 42) CHD (1; age = 13) HC (3; age = 27 ± 3.46) | Whole blood | NA | NA | NA | ↑16s rRNA gene concentration in all patients vs. HC | Blood dysbiosis in cardiac disease might be characterized by an increase in Actinobacteria but a decrease in Proteobacteria as well as an upsurge in 16s rRNA gene concentration | [ | |
| The French study (202): Patients with myocardial infarction (99; age = 58.5 (49.9–64.2)) Controls with high cardiovascular risk (103; age = 61.6 (54.9–67.2)) | Whole blood | ↓ | NA | NS |
↑16s rRNA gene concentration in the patients with myocardial infarction vs. controls | Blood dysbiosis in patients with myocardial infarction compared with controls with high cardiovascular risk may be characterized by a decrease in Cholesterol-degrading microbes, including | [ | |
|
| ||||||||
| The Korean study (398): Patients with acute ischemic stroke (198; age = 63.7 ± 12.5) Good clinical outcomes (159; age = 62.8 ± 11.8) Poor clinical outcomes (39; age = 67.5 ± 14.6) HC (200; age = 63.5 ± 12.5) | EVs | NA | NA | S | NA | Blood dysbiosis in acute ischemic stroke might be characterized by an increase in Proteobacteria but a decrease in Firmicutes | [ | |
| The Korean study (398): Patients with acute ischemic stroke (198; age = 63.7 ± 12.5) Good clinical outcomes (159; age = 62.8 ± 11.8) Poor clinical outcomes (39; age = 67.5 ± 14.6) HC (200; age = 63.5 ± 12.5) | EVs |
| [ | |||||
|
| ||||||||
| NA | NA | NS | NA | An increase in | ||||
|
| ||||||||
| The American study (40): Patients with chronic kidney disease (20; age = 56 (49–61)) HC (20; age = 44 (39–53)) | Buffy coat | ↓ | NA | NS |
Proteobacteria negatively correlated with glomerular filtration rate (r = −0.54) | Blood dysbiosis in chronic kidney disease might be characterized by an increase in Proteobacteria, which may play a role in progression of chronic kidney disease | [ | |
*: cholesterol-degrading microbes.
Blood Bacteriome Dysbiosis Profiles in Oral, Gastrointestinal, and Hepatobiliary Diseases.
| Subjects (n; Mean Age) | Samples | Dysbiotic Blood Bacteriome of Patients vs. Controls | Other | Interpretation | Ref. | |||
|---|---|---|---|---|---|---|---|---|
| Diversity | Differential Abundance | |||||||
| α-R | α-E | β | ||||||
|
| ||||||||
| The American study (41): Subjects with tobacco-smoking (20; age = 43 (32–48)) HC (21; age = 38 (30–46)) | Plasma | NA | ↑ | S | NA | Blood dysbiosis in association with tobacco smoking might be characterized by an increase in | [ | |
| The British study (40): Patients with periodontitis (18; age = 46.61 ± 15.21) HC (22; age = 39.95 ± 13.21) | Whole blood | ↕ | ↕ | S |
About 70% of blood bacteriomes in both HC and patients with periodontitis were familiar with oral microbiome (Human Oral Microbiome database) | Blood dysbiosis in periodontitis might be characterized by a decrease in Candidatus Saccharibacteria; in addition, blood bacteriome might originate from oral bacteriome | [ | |
|
| ||||||||
| The Chinese study (84): Patients with gastric cancer (71; age = 59 (52–65)) HC (13; age = NA) | Serum | NA | ↓ | S |
| Blood dysbiosis in gastric cancer might be characterized by an increase in | [ | |
|
| ||||||||
| The Danish study with colon cancer (30; age = 67.6 ± 8.8): Pre-operative patients as controls (30) Post-operative patients (30) | Whole blood | ↓ | NA | NS |
↓16s rRNA gene concentration in the post-operative patients | Blood dysbiosis in post-operative patients with colon cancer might be characterized by an increase in Proteobacteria but a decrease in Actinobacteria as well as a decline in 16s rRNA gene concentration | [ | |
| The Chinese study with colon cancer (19; age = 64 (36–81)): Patients before treated with CT as controls (19) Patients who later became drug responders (8; age = 66.5 (53–72)) Patients who later, became drug non-responders (11; age = 62 (36–81)) Patients after being treated with CT (19) | Plasma | ↕ | ↕ | NA |
↓16s rRNA gene concentration in the post-treatment patients | CT could modify blood bacteriome in colon cancer as an increase in Verrucomicrobia while 16s rRNA gene concentration was decreased | [ | |
|
| ||||||||
|
| ||||||||
| ↕ | ↕ | S | NA | An increase in Firmicutes and Fusobacteria in baseline blood bacteriome of colon cancer could predict the responsiveness of CT | ||||
| The Chinese study with colon cancer (20; age = 60 (36–86)): Patients before treatment with CT and DC-CIK as controls (20) Patients who later, became drug responders (13; age = 60 (36–78)) Patients who later, became drug non-responders (7; age = 60 (47–86)) Patients after being treated with CT and DC-CIK (20) | Plasma | ↑ | ↓ | NA |
↓16s rRNA gene concentration in the post-treatment patients | CT together with DC-CIK could modify blood bacteriome in colon cancer as an increase in Bacteroidetes while 16s rRNA gene concentration was decreased | [ | |
|
| ||||||||
|
| ||||||||
| ↓ | ↕ | NA |
| An increase in | ||||
| The British study (18): Patients with treated inflammatory bowel diseases (13; age = NA) Crohn’s disease (6; age = NA) Ulcerative colitis (7; age = NA) HC (5; age = NA) | EVs | ↕ | NA | NS | NA | NA | Blood bacteriome in treated inflammatory bowel diseases might not be different from healthy controls | [ |
|
| ||||||||
| The Chinese study (62): Patients with acute pancreatitis (50; age = 43.66 ± 11.42) HC (12; age = 29.2 ± 3.8) | Whole blood | ↑ | NA | S |
About 87% of blood bacteriome in both patients and HC was familiar with gut microbiome (HMP database) | Blood dysbiosis in acute pancreatitis might be characterized by an increase in Bacteroidetes but a decrease in Actinobacteria; moreover, blood bacteriome might originate from gut | [ | |
| The Chinese study (62): Patients with acute pancreatitis (50; age = 43.66 ± 11.42) HC (12; age = 29.2 ± 3.8) | Neutrophil | ↑ | NA | S |
About 83.1% of neutrophil bacteriome in both patients and HC were familiar with gut microbiome (HMP database) | Neutrophil dysbiosis in acute pancreatitis might be characterized by an increase in Bacteroidetes and Firmicutes but a decrease in Actinobacteria and Proteobacteria; additionally, blood bacteriome might originate from gut | [ | |
| The Korean study (155): Patients with biliary diseases (67; age = 60.56 ± 13.80) Biliary tract cancer (24; age = 69.8 ± 10.7) Either cholecystitis or cholangitis (43; age = 55.4 ± 15.5) HC (88; age = 54.4 ± 12.8) | EVs | ↕ | NA | S | NA | Blood dysbiosis in biliary diseases might be characterized by an increase in Clostridia but a decrease in Gammaproteobacteria | [ | |
|
| ||||||||
|
| ||||||||
| ↕ | NA | S | NA | Blood dysbiosis in biliary tract cancers might be characterized by an increase in | ||||
|
| ||||||||
| The American study (76): Patients with alcoholic hepatitis (37; age = 44.87 ± 10.76) HC (39; age = 41.9 ± 10.7) | Whole blood | ↕ | NA | NS |
↑16s rRNA gene concentration in the patients with alcoholic hepatitis vs. HC | Blood dysbiosis in association with alcoholic hepatitis might be characterized by a decrease in Bacteroidetes as well as an increase in 16s rRNA gene concentration | [ | |
| The morbid obese in Spanish study (37): Patients with cirrhosis (11; age = 48.1 ± 9.3; BMI = 41.9 ± 6.5) Controls without cirrhosis (26; age = 46.2 ± 8.9; BMI = 44.7 ± 6.7) | Buffy coat | ↓ | NA | NA |
↑16s rRNA gene concentration in the morbidly obese patients with cirrhosis | Blood dysbiosis in morbidly obese patients with cirrhosis compared with morbidly obese patients without cirrhosis might be characterized by an increase in Proteobacteria but a decrease in Actinobacteria as well as an increase in 16s rRNA gene concentration | [ | |
| The Korean study with NAFLD (76): Obese patients (49; age = 44.6 ± 8.1; BMI = 26.2 ± 1.1) Lean controls (27; age = 46.7 ± 8.3; BMI = 21.8 ± 1.8) | Buffy coat | NA | NA | NS | NA | Blood dysbiosis in obese patients with NAFLD might be characterized by an increase in | [ | |
| The Korean study (363): Patients with liver disease (162; age = 57.83 ± 10.16) Patients with HCC (79; age = 58.6 ± 9.6) Patients with cirrhosis (83; age = 57.1 ± 10.7) HC (201; age = 57.6 ± 10.4) | Serum | ↓ | NA | S | NA | Blood dysbiosis in liver diseases (HCC and cirrhosis) might be characterized by an increase in Proteobacteria but a decrease in Firmicutes | [ | |
|
| ||||||||
|
| ||||||||
| ↓ | NA | S | NA | Blood dysbiosis in HCC might be characterized by an increase in | ||||
| The Japanese study (80): Patients with cirrhosis (66; age = 70.2 ± 9.9) HCC (48; age = NA) HC (14; age = 37.4 ± 10) | Whole blood | ↕ | ↕ | NS | NA | Blood dysbiosis in cirrhosis might be characterized by a decrease in Erysipelotrichales but an increase in | [ | |
|
| ||||||||
|
| ||||||||
| NA | NA | NA | NA | Blood dysbiosis in HCC might be characterized by an increase in | ||||
| The Chinese study (98): Patients with HBV-DLF (50; age = 48.4 ± 13.2) Patients who died within 28 days after diagnosis (20; age = NA) Patients who survived for 28 days after diagnosed (30; age = NA) Controls (48; age = 50.81 ± 10.53) Patients with HBV-CLF (25; age = 54.4 ± 7.9) HC (23; age = 46.9 ± 13.4) | Plasma | ↕ | ↓ | NS |
↑16s rRNA gene concentration in the patients with HBV (HBV-DLF > HBV-CLF > HC) | Blood dysbiosis in HBV-DLF compared with HBV-CLF and HC might be characterized by a decrease in Actinobacteria and Deinococcus-Thermus; in addition, the liver may filter bacteriome in blood, and its efficacy might depend on liver function | [ | |
|
| ||||||||
|
| ||||||||
| ↕ | ↓ | NS | NA | Blood dysbiosis in HBV-DLF compared with HBV-CLF might be characterized by an increase in Campylobacterales but a decrease in Xanthomonadales | ||||
|
| ||||||||
| ↕ | ↓ | NS | NA | Blood dysbiosis in HBV-DLF might be characterized by a decrease in Alphaproteobacteria | ||||
|
| ||||||||
| NA | NA | NA | NA | Blood dysbiosis in HBV-DLF with poor prognosis might be characterized by an increase in | ||||
Blood Bacteriome Dysbiosis Profiles in Neurological Disorders.
| Subjects (n; Mean Age) | Samples | Dysbiotic Blood Bacteriome of Patients vs. Controls | Other | Interpretation | Ref. | |||
|---|---|---|---|---|---|---|---|---|
| Diversity | Differential Abundance | |||||||
| α-R | α-E | β | ||||||
|
| ||||||||
| The France study (112): Patients with untreated MDE (56; age = 41.9 ± 11.6) HC (56; age = 41.9 ± 12.7) | Plasma | ↕ | ↕ | S | NA | Blood dysbiosis in MDE might be characterized by a decrease in Fusobacteria and Candidatus Saccharibacteria | [ | |
| The France study (56; 41.9 ± 11.6): Patients with MDE after received 3 months of anti-depressive drugs (56) Drug responders (32; age = 40.7 ± 11.99) Drug non-responders (24; age = 43.7 ± 10.99) Patients with MDE before received anti-depressive drugs (56) | Plasma | NA | NA | NA | NA | Blood dysbiosis in MDE might be reversed by anti-depressive drugs as an increase in | [ | |
|
| ||||||||
|
| ||||||||
| NA | NA | NA | NA | MDE patients whose baseline blood has increased Firmicutes and a reduction in Proteobacteria and Actinobacteria may respond to anti-depressive drugs | ||||
| The American study (192): Patients with SCZ (48; age = 29.9 ± 5.8) Controls Patients with BP (48; age = 46.5 ± 9.9) Patients with ALS (47; age = 56.4 ± 10.3) HC (49; age = 41.1 ± 10.7) | Whole blood | NA | ↑ | S |
Composition of blood bacteriome in all groups was similar to gut and oral microbiome (HMP database) Blood bacterial diversity negatively correlated with diversity of T cell population (r = −0.41) | Human blood bacteriome may originate from gut as well as oral bacteriome, and a reduction in diversity of T cell population in SCZ might relate to blood dysbiosis, which was characterized by an increase in Planctomycetes and Thermotogae | [ | |
|
| ||||||||
| The Chinese study (90): Patients with Parkinson’s disease (45; age = 68.1 ± 8.0) HC (45; age = 67.9 ± 8.0) | Buffy coat | ↕ | ↕ | NS | NA | Blood dysbiosis in Parkinson’s disease might be characterized by an increase in | [ | |
| The Chinese study (80): Patients with MSA (40; age = 60.98 ± 6.7) Cerebellar type (17; age = 58.94 ± 7.83) Parkinsonian type (23; age = 62.48 ± 5.48) HC (40; age = 60.88 ± 7.0) | Buffy coat | ↕ | ↕ | S | NA | Blood dysbiosis in MSA might be characterized by an increase in | [ | |
|
| ||||||||
|
| ||||||||
| NA | NA | NA | NA | Blood dysbiosis in Cerebellar MSA might be characterized by an increase in | ||||
Blood Bacteriome Dysbiosis Profiles in Immunity-Mediated Diseases.
| Subjects (n; Mean Age) | Samples | Dysbiotic Blood Bacteriome of Patients vs. Controls | Other | Interpretation | Ref. | |||
|---|---|---|---|---|---|---|---|---|
| Diversity | Differential Abundance | |||||||
| α-R | α-E | β | ||||||
|
| ||||||||
| The American (40): Well-treated SLE patients (21; age = 36.8 ± 9.9) HC (19; age = 34.2 ± 9.4) | Plasma | ↕ | ↕ | NS | NA | Blood dysbiosis in well-treated SLE might be characterized by an increase in Fusobacteria | [ | |
| The American (36): First-degree relatives of SLE patients (18; age = 39.4 ± 12.0) HC (18; age = 38.6 ± 12.4) | Plasma | ↓ | ↓ | S | NA | Blood dysbiosis in first-degree relatives of SLE patients might be characterized by a decrease in Firmicutes | [ | |
| The American (49): SLE patients (19; age = 35 (30–48)) HC (30; age = 43 (32–56)) | Plasma | NA | NA | NA |
↑TNF-α, ↑IL-1β, and ↑IL-6 from PBMC inoculated with Planococcus | An increase in | [ | |
| The Chinese (42): Patients with rheumatoid arthritis (28; age = 44.99 ± 9.45) HC (15; age = 50.48 ± 14.05) | PBMCDNA | ↕ | ↕ | S | Blood dysbiosis in rheumatoid arthritis may be characterized by an increase in Candidatus Saccharibacteria, but a decrease in Bacteroidetes and an increase in | [ | ||
| The British (30): Patients with untreated rheumatoid arthritis (20; age = NA) Controls (10; age = NA) HC (4; age = NA) Well-treated ankylosing spondylitis (4; age = NA) Well-treated psoriatic arthritis (2; age = NA) | Serum DNA | NA | NA | NA | NA | Blood dysbiosis in rheumatoid arthritis might be characterized by an increase in | [ | |
| The British (20; age = NA): Patients with rheumatoid arthritis after 3 months of anti-rheumatic treatment (20) Patients with rheumatoid arthritis before treated with anti-rheumatic drugs (20) | Serum DNA | NA | NA | NA | NA | Anti-rheumatic drugs might cause a reversion of blood dysbiosis in rheumatoid arthritis by an increase in | [ | |
| The Taiwanese (28): Patients with psoriasis (20; age = 44.45 ± 16.51) HC (8; age = 49.63 ± 15.16) | EVsDNA | ↓ | ↓ | S | NA | Blood dysbiosis in psoriasis might be characterized by a decrease in Firmicutes and Fusobacteria | [ | |
| The French (47): Patients with large vessel arteritis (31; age = 53.77 ± NA) GCA (11; age = 74.08 ± NA) Active (6; age = 77.4 ± NA) Inactive (5; age = 70.1 ± NA) TAK (20; age = 42.6 ± NA) Active (10; age = 43.8 ± NA) Inactive (10; age = 41.4 ± NA) HC (15; age = NA) | Serum DNA | ↕ | ↕ | NS | NA | Blood dysbiosis in large vessel arteritis might be characterized by an increase in Cytophagia and Clostridia | [ | |
|
| ||||||||
|
| Blood dysbiosis in both GCA and TAK characterized by an increase in Cytophagia and an upsurge in | |||||||
| NA | NA | NA | NA | |||||
|
| ||||||||
| NA | NA | NA | NA | |||||
|
| ||||||||
| NA | NA | NA | NA | |||||
|
| ||||||||
| NA | NA | NA | Genus: ↑ | NA | ||||
|
| ||||||||
| The Korean (40): Patients with rosacea (10; age = NA) HC (30; age = NA) | Whole blood | ↕ | ↕ | S | NA | Blood dysbiosis in rosacea might be characterized by an increase in | [ | |
|
| ||||||||
| The British (10): Patients with asthma (5; age = 39.6 ± 11.7) HC (5; age = 39.4 ± 10.3) | Plasma | ↕ | ↕ | NA | NA | Blood dysbiosis in asthma might be characterized by an increase in Firmicutes and Bacteroidetes but a decrease in Proteobacteria | [ | |
| The Korean (450): Patients with asthma (190; age = 48.8 ± 14.6) Steroid naïve (21; age = NA) ICS only (156; age = NA) ICS and OCS (12; age = NA) Unknown (1; age = NA) HC (260; age = 56) | EVsDNA | ↑ | ↓ | S | NA | Blood dysbiosis in treated and untreated asthma might be characterized by an increase in Bacteroidetes and Actinobacteria but a decrease in Verrucomicrobia and Cyanobacteria | [ | |
|
| ||||||||
|
| ||||||||
| NA | NA | NA | NA | Asthma treated with steroids might affect blood bacteriome by a decrease in | ||||
|
| ||||||||
| NA | NA | NA | NA | Asthma treated with a combination of ICS and OCS compared with ICS only might affect blood bacteriome by an increase in | ||||
Figure 1Schematic illustration of the current understanding of the blood bacteriome. (Red box) Gut, the colon in particular, oral, and lung bacteriomes may be the primary sources of the blood bacteriome, several factors potentially influencing the translocation of the bacteria. (Gray box) The liver could filter the blood bacteriome, especially Proteobacteria, and liver diseases may cause a deterioration of this function. (Green box) The Cholesterol-degrading Aerococcaceae may play a role in the amelioration of ischemic stroke and prevention of AMI. AMI—acute myocardial infarction, hCV—high cardiovascular risk, HIV—human immunodeficiency virus, cART—combined anti-retroviral therapy, T2DM—type 2 diabetes mellitus, HBV—hepatitis B virus infection, SLE—systemic lupus erythematosus, TNF—tumor necrosis factor, IL—interleukin, CRP—C-reactive protein, LBP—LPS-binding protein.